MX2019005101A - Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. - Google Patents

Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.

Info

Publication number
MX2019005101A
MX2019005101A MX2019005101A MX2019005101A MX2019005101A MX 2019005101 A MX2019005101 A MX 2019005101A MX 2019005101 A MX2019005101 A MX 2019005101A MX 2019005101 A MX2019005101 A MX 2019005101A MX 2019005101 A MX2019005101 A MX 2019005101A
Authority
MX
Mexico
Prior art keywords
halouracil
nucleic acid
present disclosure
compositions
cancer
Prior art date
Application number
MX2019005101A
Other languages
English (en)
Spanish (es)
Inventor
Ju Jingfang
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of MX2019005101A publication Critical patent/MX2019005101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019005101A 2016-11-01 2017-10-30 Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. MX2019005101A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662415740P 2016-11-01 2016-11-01
US201662422298P 2016-11-15 2016-11-15
US201762464491P 2017-02-28 2017-02-28
PCT/US2017/059011 WO2018085198A1 (en) 2016-11-01 2017-10-30 5-halouracil-modified micrornas and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019005101A true MX2019005101A (es) 2019-08-22

Family

ID=62077036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005101A MX2019005101A (es) 2016-11-01 2017-10-30 Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.

Country Status (12)

Country Link
US (2) US11584932B2 (de)
EP (2) EP3534912A4 (de)
JP (2) JP7130639B2 (de)
KR (2) KR102502248B1 (de)
CN (2) CN110290794A (de)
AU (2) AU2017353907B2 (de)
BR (1) BR112019008810A2 (de)
CA (1) CA3042401A1 (de)
IL (1) IL282836A (de)
MX (1) MX2019005101A (de)
SG (1) SG11202104571RA (de)
WO (2) WO2018085198A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3030679A4 (de) * 2013-08-08 2017-04-12 The Research Foundation for The State University of New York Keratine als biomarker für gebärmutterhalskrebs und überleben
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CA3042401A1 (en) * 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
KR20210139237A (ko) * 2019-03-14 2021-11-22 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 변형된 마이크로rna 및 암 치료에 있어서의 이의 용도
CA3175539A1 (en) * 2020-03-18 2021-09-23 The Research Foundation For The State University Of New York Modified short-interfering rna compositions and their use in the treatment of cancer
WO2021262919A2 (en) * 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
EP2390331B1 (de) * 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MikroRNA-Moleküle
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20050261217A1 (en) 2004-05-18 2005-11-24 Isis Pharmaceuticals Inc. Modulation of pumilio 1 expression
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US20070259349A1 (en) 2006-05-04 2007-11-08 Itzhak Bentwich Bladder cancer-related nucleic acids
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
EP2302055B1 (de) 2004-11-12 2014-08-27 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNAa-inhibitorischen Molekülen verbunden sind
US8071559B2 (en) 2005-05-02 2011-12-06 Cold Spring Harbor Laboratory Compositions and methods for cancer diagnosis and treatment
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
EP2377559A1 (de) 2005-06-03 2011-10-19 Southern Adelaide Health Service - Flinders Medical Centre Targeting von Zellen mit veränderter microRNA-Expression
CN103820562B (zh) 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN103028120B (zh) * 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
EP2468891B1 (de) 2006-01-05 2015-04-29 The Ohio State University Research Foundation Verfahren auf Mikro-RNA-Basis zur Diagnose von Prostatakrebs oder Magenkrebs
EP1968622B1 (de) 2006-01-05 2014-08-27 The Ohio State University Research Foundation Mikro-rna-expressions-anomalien in pankreas- und azinus-tumoren
EP1991706B1 (de) 2006-03-02 2014-01-15 The Ohio State University Research Foundation Mikro-rna-expressionsprofil im zusammenhang mit bauchspeicheldrüsenkrebs
EP2369011A1 (de) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Miko-RNA-Fingerabdrücke während humaner Megakaryozytopoiese
ES2569558T3 (es) 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
EP2436785B1 (de) 2006-07-13 2013-09-11 The Ohio State University Research Foundation Micro-ARN-29a zur Diagnose von Darm Adenokarzinom mit schlechter Uberlebensprognose.
WO2008014008A2 (en) 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
JP2010504349A (ja) * 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−１４３によって調節される遺伝子および経路
EP2076599A2 (de) 2006-09-19 2009-07-08 Asuragen, Inc. Mir-200-regulierte gene und wege als ziele für einen therapeutischen eingriff
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP3536788A1 (de) 2006-12-21 2019-09-11 QIAGEN GmbH Mikro-rna-zielortblockierende oligos und verwendungen davon
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
US8389486B2 (en) 2007-01-26 2013-03-05 Rosetta Genomics, Ltd Methods for treating hematopoietic malignancies
US20100310583A1 (en) 2007-01-31 2010-12-09 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
CA2686165A1 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising mir34 therapeutic agents for treating cancer
EP2179060B1 (de) * 2007-07-18 2013-11-27 The Regents of the University of Colorado DIFFERENZIELLE EXPRESSION VON microRNA BEI FUNKTIONIERENDEN IM VERGLEICH ZU NICHTFUNKTIONIERENDEN MENSCHLICHEN HERZEN
AU2008296022B2 (en) 2007-09-06 2014-01-23 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
CN101842484B (zh) * 2007-09-14 2015-07-29 俄亥俄州立大学研究基金会 人外周血微泡中的mirna表达和其用途
US8361714B2 (en) * 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090136957A1 (en) 2007-09-15 2009-05-28 Irena Ivanovska Methods and compositions for regulating cell cycle progression via the miR-106B family
US20100285471A1 (en) 2007-10-11 2010-11-11 The Ohio State University Research Foundation Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
CA2704043C (en) 2007-10-29 2018-09-18 Rosetta Genomics Ltd. Targeting micrornas for the treatment of liver cancer
US20110009469A1 (en) 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
US20110054009A1 (en) 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
WO2009120712A2 (en) 2008-03-24 2009-10-01 New York University Compositions and methods for diagnosing and treating melanoma
EP2271757A2 (de) 2008-03-26 2011-01-12 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit mir-16 und prostatakrebstherapie
US20100113284A1 (en) 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
WO2009126726A1 (en) 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US20110166200A1 (en) 2008-04-24 2011-07-07 Zhan Zhang Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
EP2296669B1 (de) 2008-05-30 2012-03-21 Yale University Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
WO2009147658A2 (en) 2008-06-02 2009-12-10 New York University Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
US8927207B2 (en) * 2008-06-05 2015-01-06 Research Foundation Of State University Of New York miRNAs as therapeutic targets in cancer
US9540695B2 (en) 2008-06-17 2017-01-10 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
US20110118337A1 (en) 2008-07-10 2011-05-19 Merck Sharp & Dohme Corp. Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
WO2010023658A2 (en) 2008-08-28 2010-03-04 Rosetta Genomics Ltd. Compositions and methods for the treatment of glioblastoma
KR101770435B1 (ko) 2008-10-03 2017-09-05 큐알엔에이, 인크. 자연 안티센스 전사체가 아포리포단백질-ａ1로 억제에 의해 아포리포단백-ａ1 관련된 질환의 치료
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
ES2637063T3 (es) 2008-12-04 2017-10-10 Curna, Inc. Tratamiento de enfermedades relacionadas con genes supresores de tumor mediante inhibición del transcrito antisentido natural al gen
JP5971948B2 (ja) 2008-12-04 2016-08-17 クルナ・インコーポレーテッド Ｖｅｇｆに対する天然アンチセンス転写物の抑制による血管内皮増殖因子（ｖｅｇｆ）関連疾患の治療
KR101749352B1 (ko) 2008-12-04 2017-06-20 큐알엔에이, 인크. Ｓｉｒｔ1에 대한 천연 안티센스 전사체의 억제에 의해 ｓｉｒｔ1 관련된 질환의 치료
AU2009322907B2 (en) 2008-12-05 2016-05-05 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
US20100311815A1 (en) 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
US20100233704A1 (en) * 2009-02-25 2010-09-16 Cepheid Methods of detecting lung cancer
JP6250263B2 (ja) 2009-03-04 2017-12-20 クルナ・インコーポレーテッド サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるｓｉｒｔ１関連疾患の治療
US8735568B2 (en) 2009-03-09 2014-05-27 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
WO2010108192A1 (en) * 2009-03-20 2010-09-23 The Research Foundation Of State University Of New York Mirnas as therapeutic targets in cancer
WO2010115050A2 (en) * 2009-04-01 2010-10-07 The Regents Of The University Of California Embryonic stem cell specific micrornas promote induced pluripotency
AU2010242163B2 (en) * 2009-04-29 2014-10-16 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
CN102639151B (zh) 2009-05-01 2017-03-22 库尔纳公司 通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白（hbf/hbg）相关疾病
CA2761142C (en) 2009-05-06 2021-06-08 Opko Curna, Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
KR100998365B1 (ko) * 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
WO2011014980A1 (en) 2009-08-07 2011-02-10 Capitalbio Corporation Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival
US8822144B2 (en) 2009-08-19 2014-09-02 Rosetta Genomics Ltd. Compositions and methods for prognosis and treatment of prostate cancer
WO2011024157A1 (en) 2009-08-23 2011-03-03 Rosetta Genomics Ltd. Nucleic acid sequences related to cancer
US9157080B2 (en) 2009-09-09 2015-10-13 New York University Compositions and methods for treatment, diagnosis and prognosis of mesothelioma
CA2780222C (en) * 2009-11-04 2021-11-16 Diamir, Llc Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
RU2611186C2 (ru) 2009-12-29 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
JP5886757B2 (ja) 2010-01-04 2016-03-16 カッパーアールエヌエー，インコーポレイテッド インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
WO2011088309A1 (en) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
NO2529015T3 (de) 2010-01-25 2018-04-14
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
WO2011108930A1 (en) * 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011116152A2 (en) 2010-03-16 2011-09-22 Sanford -Burnham Medical Research Institute Delivery of agents using interfering nanoparticles
CN102858979B (zh) 2010-04-09 2018-01-26 库尔纳公司 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
WO2011128886A1 (en) 2010-04-12 2011-10-20 Ramot At Tel Aviv University Ltd. A micro-rna for cancer diagnosis, prognosis and therapy
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
TW201201819A (en) 2010-05-19 2012-01-16 Opko Curna Llc Treatment of BCL2-like 11 (BCL2L11) related diseases by inhibition of natural antisense transcript to BCL2L11
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
WO2012009347A2 (en) 2010-07-12 2012-01-19 Opko Curna Llc Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
WO2012009508A2 (en) 2010-07-15 2012-01-19 Emory University Microrna compositions and methods related thereto
WO2012014190A2 (en) 2010-07-25 2012-02-02 New York University Compositions and methods for prognosis of mesothelioma
EP2598657B1 (de) 2010-08-01 2016-10-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Mirna-muster für die diagnose, prognose und behandlung von melanomen
ES2640755T3 (es) 2010-10-06 2017-11-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
KR101343616B1 (ko) 2010-10-08 2013-12-20 연세대학교 산학협력단 췌장암 치료용 약제학적 조성물 및 췌장암 치료제 스크리닝 방법
EP3702460A1 (de) 2010-11-12 2020-09-02 The General Hospital Corporation Polycombassoziierte nichtcodierende rnas
JP2014502606A (ja) 2010-12-15 2014-02-03 メディミューン，エルエルシー 黒色腫の処置
AR093183A1 (es) * 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
WO2012093384A1 (en) 2011-01-03 2012-07-12 Rosetta Genomics Ltd. Compositions and methods for treatment of ovarian cancer
EP2474617A1 (de) * 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
WO2012106586A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
US9132152B2 (en) 2011-02-10 2015-09-15 The Regents Of The University Of California Compositions and methods for generating induced pluripotent stem cells
WO2012128902A1 (en) 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
US8987224B2 (en) * 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
US20150267193A1 (en) * 2011-10-14 2015-09-24 Ramanuj Dasgupta MicroRNAs and Methods of Using Same
US20140323551A1 (en) 2011-11-30 2014-10-30 Cedars-Sinai Medical Center Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
US9745578B2 (en) 2011-11-30 2017-08-29 Cedars-Sinai Medical Center Targeting microRNA miR-409-3P to treat prostate cancer
WO2013109604A1 (en) * 2012-01-19 2013-07-25 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
TR201815503T4 (tr) 2012-03-15 2018-11-21 Curna Inc Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
US20150211004A1 (en) * 2012-04-20 2015-07-30 Agency For Science, Technology And Research Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
AU2013262702A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating BDNF expression
CN104583399A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节血红蛋白基因家族表达的组合物和方法
AU2013262663A1 (en) 2012-05-16 2015-01-22 The General Hospital Corporation D/B/A Massachusetts General Hospital Compositions and methods for modulating gene expression
BR112014028634A2 (pt) 2012-05-16 2017-06-27 Rana Therapeutics Inc composições e métodos para modulação da expressão de utrn
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
JP2015523853A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｔｐ２ａ２発現を調節するための組成物及び方法
WO2013173605A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating pten expression
JP2015523855A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法
CA2882428A1 (en) 2012-07-12 2014-01-16 Baylor College Of Medicine Micrornas sensitize cancers to therapy
US9096853B2 (en) * 2012-09-24 2015-08-04 U.S. Department Of Veterans Affairs Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
EP2914344B1 (de) 2012-10-31 2020-01-15 The Rockefeller University Behandlung von metastatischen darmkrebs
EP3800256A1 (de) 2012-11-06 2021-04-07 InteRNA Technologies B.V. Kombination zur therapeutischen verwendung bei krankheiten oder zuständen im zusammenhang mit melanomen oder bei krankheiten oder zuständen im zusammenhang mit dem aktivierten b-raf-signalweg
US9416369B2 (en) * 2012-12-18 2016-08-16 University Of Washington Through Its Center For Commercialization Methods and compositions to modulate RNA processing
WO2014186462A1 (en) * 2013-05-15 2014-11-20 The Research Foundation For The State University Of New York Microrna-129 as a biomarker for colorectal cancer
JP2016521556A (ja) 2013-06-07 2016-07-25 ラナ セラピューティクス インコーポレイテッド Ｆｏｘｐ３発現を調節するための組成物及び方法
US20150151004A1 (en) * 2013-06-14 2015-06-04 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
WO2015066034A1 (en) * 2013-10-28 2015-05-07 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
US20160312301A1 (en) 2013-12-20 2016-10-27 The Feinstein Institute For Medical Research Microrna biomarkers for ovarian cancer
EP3105327A4 (de) 2014-02-12 2017-10-18 Thomas Jefferson University Zusammensetzungen und verfahren zur verwendung von mikrorna-inhibitoren
KR101596166B1 (ko) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 유방암 진단 및 치료를 위한 마이크로 ｒｎａ의 용도
EP3271460A4 (de) 2015-03-17 2019-03-13 The General Hospital Corporation Rna-interaktom des polycomb-repressiven komplexes 1 (prc1)
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
US10053696B2 (en) 2016-01-21 2018-08-21 University Of South Carolina MiRNA-489 in treatment of breast cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CA3042401A1 (en) 2016-11-01 2018-05-11 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
US10988766B2 (en) 2017-01-06 2021-04-27 Oregon Health & Science University Compositions and methods used in diagnosing and treating colorectal cancer
WO2018136919A2 (en) 2017-01-23 2018-07-26 Trustees Of Boston University Methods relating to lung cancer
KR101953300B1 (ko) 2018-06-22 2019-02-28 의료법인 성광의료재단 탁산계 항암제 내성 암의 진단 및 치료를 위한 조성물, 키트 및 방법
EP3852814A4 (de) 2018-09-20 2022-09-14 ModernaTX, Inc. Zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
TW202031268A (zh) 2018-11-13 2020-09-01 美商雷格勒斯治療公司 用於調節mir-10b 活性之微小rna 化合物及方法
WO2020154207A1 (en) 2019-01-22 2020-07-30 Research Institute At Nationwide Children's Hospital A novel method for monitoring and treating oral cancer
KR20210139237A (ko) 2019-03-14 2021-11-22 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 변형된 마이크로rna 및 암 치료에 있어서의 이의 용도
WO2021097437A1 (en) 2019-11-14 2021-05-20 The Board Of Regents Of The University Of Oklahoma Oligonucleotide interference treatments of prostate cancer
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer

Also Published As

Publication number Publication date
US20190062754A1 (en) 2019-02-28
BR112019008810A2 (pt) 2019-07-16
CN110290794A (zh) 2019-09-27
AU2019371830A1 (en) 2021-06-03
US20230365972A1 (en) 2023-11-16
KR102502248B1 (ko) 2023-02-21
WO2018085198A1 (en) 2018-05-11
AU2017353907B2 (en) 2023-11-30
AU2017353907A1 (en) 2019-05-23
EP3873613A4 (de) 2023-11-15
SG11202104571RA (en) 2021-06-29
WO2020092466A1 (en) 2020-05-07
EP3534912A4 (de) 2020-10-07
CA3042401A1 (en) 2018-05-11
KR20190086688A (ko) 2019-07-23
US11584932B2 (en) 2023-02-21
JP2019533697A (ja) 2019-11-21
CN113573781A (zh) 2021-10-29
JP7130639B2 (ja) 2022-09-05
KR20210088614A (ko) 2021-07-14
EP3873613A1 (de) 2021-09-08
EP3534912A1 (de) 2019-09-11
JP2022173194A (ja) 2022-11-18
IL282836A (en) 2021-06-30
JP7498230B2 (ja) 2024-06-11

Similar Documents

Publication Publication Date Title
MX2019005101A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
SA519401379B1 (ar) علاج فيروس مرتبط بغدة لمرض هنتنجتون
RU2017132895A (ru) Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
PH12017500669A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2016205410A3 (en) Defined multi-conjugate oligonucleotides
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
SA518400552B1 (ar) مركبات فوسفوراميدات
MX2019006475A (es) Sistemas y métodos para dirección con arn guía puntual (arngp) de adn endógeno y fuente.
EA201791820A1 (ru) Олигонуклеотидная терапия врожденного амавроза лебера
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
BR112014028787A2 (pt) método para tratamento de câncer de pulmão de célula não pequena
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
MX2019015188A (es) Inserciones de adn no virales orientadas.
EP3620178A3 (de) Antibakterielle antisense-verbindungen und verfahren
MD4760B1 (ro) Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
CA3156667A1 (en) OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS
MX2018005872A (es) Profarmacos de acido nucleico.
IN2014CN03921A (de)
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
EA201792261A1 (ru) Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
WO2021262919A3 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
WO2020172274A8 (en) Targeting micrornas to overcome drug tolerance and resistance